World Wires · story 20914 · unverified · 1 source(s)

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing

Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing.

Open in the desk

Coverage

• Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing GlobeNewswire: public companies · tier D · clear net · 2026-10-05 12:00 UTC

What this site indexes